Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123018237> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3123018237 endingPage "1256" @default.
- W3123018237 startingPage "1256" @default.
- W3123018237 abstract "1256 Background: Zoledronate is a bisphosphonate that accumulates at sites of high bone turnover. Radiolabeled Zoledronate has been successfully demonstrated in clinical imaging of skeletal metastasis. 68Ga-NODAGA-Zoledronate PET/CT with 68Ga-PSMA PET/CT has, in recent times, joined 99mTc-MDP bone scan as radionuclide options for the assessment of skeletal metastasis. Bone is a common site of prostate cancer (PCa) metastasis. We aimed to compare the diagnostic ability of 68Ga-PSMA PET/CT, 68Ga-NODAGA-Zoledronate PET/CT, and 99mTc-MDP bone scan in the detection of skeletal metastases in the staging of treatment-naive men with intermediate- to high-risk PCa. Methods: Men with newly diagnosed adenocarcinoma of the prostate gland were prospectively recruited to undergo, within four weeks, imaging with 68Ga-PSMA PET/CT, 68Ga-NODAGA-Zoledronate PET/CT, and 99mTc-MDP bone scan for the assessment of skeletal metastasis. Two experienced readers independently performed image analysis. Per patient and per lesion analyses were done and compared between imaging tests. The SUVmax of the most intense lesion was compared between 68Ga-PSMA PET/CT and 68Ga-NODAGA-Zoledronate PET/CT. Results: Ten men were included with median age, Gleason score and PSA of 68.5 years (Interquartile range, IQR=63 - 74), 8 (IQR=8-9) and 119.29 ng/mL (IQR=25 - 280.58), respectively. On per-patient analysis, skeletal metastasis was detected in all patients on all three imaging tests. On a per lesion analysis, 68Ga-PSMA PET/CT identified more lesions (n=213 skeletal metastases) compared with 68Ga-NODAGA-Zoledronate PET/CT (n=174 skeletal metastases) and 99mTc-MDP bone scan (n=153 skeletal metastases), p=0.355. The mean SUVmax of the most intense lesion was 20.26 ± 7.56 for 68Ga-PSMA PET/CT compared with 14.82 ± 7.93 for 68Ga-NODAGA-Zoledronate PET/CT, p=0.227. Conclusion: On a per-patient basis, 68Ga-PSMA PET/CT, 68Ga-NODAGA-Zoledronate PET/CT, and 99mTc-MDP bone scan have a comparable performance for the detection of skeletal metastases in men with intermediate- to high-risk PCa. On a per lesion analysis, the seeming better performance of 68Ga-PSMA PET/CT in detecting more skeletal metastases than 68Ga-NODAGA-Zoledronate PET/CT and 99mTc-MDP bone scan did not reach statistical significance." @default.
- W3123018237 created "2021-02-01" @default.
- W3123018237 creator A5003840634 @default.
- W3123018237 creator A5008293723 @default.
- W3123018237 creator A5014780111 @default.
- W3123018237 creator A5015508507 @default.
- W3123018237 creator A5040501350 @default.
- W3123018237 creator A5044446326 @default.
- W3123018237 creator A5045912194 @default.
- W3123018237 creator A5057397331 @default.
- W3123018237 date "2020-05-01" @default.
- W3123018237 modified "2023-10-03" @default.
- W3123018237 title "Assessment of skeletal metastasis in prostate cancer staging: an intra-individual comparison of68Ga-PSMA PET/CT,68Ga-NODAGA-Zoledronate PET/CT, and99mTc-MDP bone scan" @default.
- W3123018237 hasPublicationYear "2020" @default.
- W3123018237 type Work @default.
- W3123018237 sameAs 3123018237 @default.
- W3123018237 citedByCount "0" @default.
- W3123018237 crossrefType "journal-article" @default.
- W3123018237 hasAuthorship W3123018237A5003840634 @default.
- W3123018237 hasAuthorship W3123018237A5008293723 @default.
- W3123018237 hasAuthorship W3123018237A5014780111 @default.
- W3123018237 hasAuthorship W3123018237A5015508507 @default.
- W3123018237 hasAuthorship W3123018237A5040501350 @default.
- W3123018237 hasAuthorship W3123018237A5044446326 @default.
- W3123018237 hasAuthorship W3123018237A5045912194 @default.
- W3123018237 hasAuthorship W3123018237A5057397331 @default.
- W3123018237 hasConcept C121608353 @default.
- W3123018237 hasConcept C126322002 @default.
- W3123018237 hasConcept C126838900 @default.
- W3123018237 hasConcept C142724271 @default.
- W3123018237 hasConcept C2775842073 @default.
- W3123018237 hasConcept C2776541429 @default.
- W3123018237 hasConcept C2777251235 @default.
- W3123018237 hasConcept C2777783956 @default.
- W3123018237 hasConcept C2779013556 @default.
- W3123018237 hasConcept C2780192828 @default.
- W3123018237 hasConcept C2781156865 @default.
- W3123018237 hasConcept C2989005 @default.
- W3123018237 hasConcept C71924100 @default.
- W3123018237 hasConceptScore W3123018237C121608353 @default.
- W3123018237 hasConceptScore W3123018237C126322002 @default.
- W3123018237 hasConceptScore W3123018237C126838900 @default.
- W3123018237 hasConceptScore W3123018237C142724271 @default.
- W3123018237 hasConceptScore W3123018237C2775842073 @default.
- W3123018237 hasConceptScore W3123018237C2776541429 @default.
- W3123018237 hasConceptScore W3123018237C2777251235 @default.
- W3123018237 hasConceptScore W3123018237C2777783956 @default.
- W3123018237 hasConceptScore W3123018237C2779013556 @default.
- W3123018237 hasConceptScore W3123018237C2780192828 @default.
- W3123018237 hasConceptScore W3123018237C2781156865 @default.
- W3123018237 hasConceptScore W3123018237C2989005 @default.
- W3123018237 hasConceptScore W3123018237C71924100 @default.
- W3123018237 hasOpenAccess W3123018237 @default.
- W3123018237 hasRelatedWork W1971222741 @default.
- W3123018237 hasRelatedWork W2038941102 @default.
- W3123018237 hasRelatedWork W2553708763 @default.
- W3123018237 hasRelatedWork W2566384684 @default.
- W3123018237 hasRelatedWork W2639796852 @default.
- W3123018237 hasRelatedWork W2744891082 @default.
- W3123018237 hasRelatedWork W2788389042 @default.
- W3123018237 hasRelatedWork W2805012316 @default.
- W3123018237 hasRelatedWork W2884198111 @default.
- W3123018237 hasRelatedWork W3000320180 @default.
- W3123018237 hasRelatedWork W3016751867 @default.
- W3123018237 hasRelatedWork W3025496289 @default.
- W3123018237 hasRelatedWork W3028553578 @default.
- W3123018237 hasRelatedWork W3045928176 @default.
- W3123018237 hasRelatedWork W3089045715 @default.
- W3123018237 hasRelatedWork W3093961849 @default.
- W3123018237 hasRelatedWork W3119774391 @default.
- W3123018237 hasRelatedWork W3135400318 @default.
- W3123018237 hasRelatedWork W3158475173 @default.
- W3123018237 hasRelatedWork W3182336628 @default.
- W3123018237 hasVolume "61" @default.
- W3123018237 isParatext "false" @default.
- W3123018237 isRetracted "false" @default.
- W3123018237 magId "3123018237" @default.
- W3123018237 workType "article" @default.